Olanzapine concentrations in dried blood spot vs. plasma
PELCOVÁ, Marta, Jan JUŘICA, Radka VAŇUŠANÍKOVÁ, Ondřej PEŠ and Zdeněk GLATZ. Olanzapine concentrations in dried blood spot vs. plasma. 2022. |
Other formats:
BibTeX
LaTeX
RIS
|
Basic information | |
---|---|
Original name | Olanzapine concentrations in dried blood spot vs. plasma |
Name in Czech | Koncenrace olanzapinu v suché kapce krve vs. plasmě |
Name (in English) | Olanzapine concentrations in dried blood spot vs. plasma |
Authors | PELCOVÁ, Marta, Jan JUŘICA, Radka VAŇUŠANÍKOVÁ, Ondřej PEŠ and Zdeněk GLATZ. |
Edition | 2022. |
Other information | |
---|---|
Type of outcome | Conference abstract |
Confidentiality degree | is not subject to a state or trade secret |
Keywords (in Czech) | olanzapin, plasma, suchá kapce krve, korelace |
Keywords in English | olanzapine, plasma, dried blood spot, correlation |
Changed by | Changed by: Mgr. Marta Pelcová, Ph.D., učo 14045. Changed: 29/11/2022 12:46. |
Abstract |
---|
Olanzapine (OLA) is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar disorder nearly 20 years ago. Therapeutic drug monitoring is strongly recommended according to the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology, and the therapeutic range of 20 to 80 ng/mL in plasma has been proposed. Dried blood spot (DBS) represents mini-invasive microsampling method, but no reference range has been established yet. The developed LC-MS method offers short analysis cycle time (12 min) with satisfactory sensitivity covering recommended OLA therapeutic concentration range in both types of samples (plasma and DBS). Primary patient plasma and DBS samples were acquired, quantified and preliminary comparison results were derived. |
Abstract (in Czech) |
---|
Olanzapine je atypické antipsychotikum schválené k léčbě schizofrenie a bipolární porucha již před 20 roky. Bylo vydáno doporučení pro terapeutické monitorování léčby s doporučeným rozmezím 20-80 ng/ml. Chuchá krevní skvrny představuje velmi málo invazivní odběrovou metodu. Refenční pro tento typ vzorku ještě nebylo stanoveno. Vyvinutá LC-MS metoda nabízí krátký čas analýzy dobrou citlivostí pokrývající terapeutické koncentrační rozmezí OLA ve dvou typech vzorků (plasmě a DBS). Vzorky pacientů byly po doručení do laboratoře zpracovány, kvantifikovány a bylo provedeno porovnání získaných hodnot. |
Abstract (in English) |
---|
Olanzapine (OLA) is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar disorder nearly 20 years ago. Therapeutic drug monitoring is strongly recommended according to the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology, and the therapeutic range of 20 to 80 ng/mL in plasma has been proposed. Dried blood spot (DBS) represents mini-invasive microsampling method, but no reference range has been established yet. The developed LC-MS method offers short analysis cycle time (12 min) with satisfactory sensitivity covering recommended OLA therapeutic concentration range in both types of samples (plasma and DBS). Primary patient plasma and DBS samples were acquired, quantified and preliminary comparison results were derived. |
Links | |
---|---|
MUNI/G/1464/2018, interní kód MU | Name: Nové směry v bioanalytických přístupech pro personalizovanou farmakoterapii schizofrenie (Acronym: TDM olanzapinu v DBS) |
Investor: Masaryk University, INTERDISCIPLINARY - Interdisciplinary research projects |
PrintDisplayed: 26/8/2024 17:54